Приклади вживання Adjuvant therapy Англійська мовою та їх переклад на Українською
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Better effect in complex and adjuvant therapy.
In advanced-stage endometrial cancer, adjuvant therapy is typically radiation, chemotherapy, or a combination of the two.
Some forms of cancer fail to benefit from adjuvant therapy.
Adjuvant therapy is particularly effective in certain types of cancer, including colorectal carcinoma, lung cancer, and medulloblastoma.
The main goal-to reduce the risk of the disease returning in the future- adjuvant therapy.
Strong synergistic effect in complex and adjuvant therapy and faster recovery time.
Adjuvant therapy in breast cancer is used in stage one and two breast cancer following lumpectomy, and in stage three breast cancer due to lymph node involvement.
An adjuvant agent modifies the effect of another agent, so adjuvant therapy modifies other therapy. .
Most areas of research include cancer adjuvant therapy, reducing stress and anxiety, promoting relaxation, improving learning and concentration, etc.
As is the case for all reproductive cancers, a degree of cautionis taken when deciding to use adjuvant therapy to treat early stage testicular cancer.
Most areas of research include cancer adjuvant therapy, reducing stress and anxiety, promoting relaxation, improving learning and concentration, etc.
In 449 children aged 3 to 12 years with epilepsy during clinical trials with gabapentin, the following side effects were observed,which were not observed with adjuvant therapy in adults:.
Depending on what form of treatment is used, adjuvant therapy can have side effects, like all therapy for neoplasms.
The term"adjuvant therapy," derived from the Latin term adjuvāre, meaning"to help," was first coined by Paul Carbone and his team at the National Cancer Institute in 1963.
In 2015, a comprehensive meta-analysis of 47 trials and11,107 patients revealed that NSCLC patients benefit from adjuvant therapy in the form of chemotherapy and/or radiotherapy.
Tamoxifen can be started either after surgery(adjuvant therapy) or before surgery(neoadjuvant therapy) and is usually taken for 5 to 10 years.
Because the treatment is essentially for a risk, rather than for provable disease,it is accepted that a proportion of patients who receive adjuvant therapy will already have been cured by their primary surgery.
Adjuvant therapy with small doses of Roferon-A increases the length of time without relapse in patients without lymph nodes and distant metastases after resection of melanoma(tumor thicknessgt; 1.5 mm).
The disease free survival is usually used to analyze the results of the treatment for the localized disease whichrenders the patient apparently disease free, such as surgery or surgery plus adjuvant therapy.
Adjuvant therapy, also known as adjunct therapy, add-on therapy, and adjuvant care, is therapy that is given in addition to the primary or initial therapy to maximize its effectiveness.
A number of studies are currently underway to determine whether immunomodulatory agents which have proveneffective in the metastatic setting are of benefit as adjuvant therapy for patients with resected stage 3 or 4 disease.
In breast cancer, adjuvant therapy may consist of chemotherapy(doxorubicin, herceptin, paclitaxel, docetaxel, cyclophosphamide, fluorouracil, and methotrexate) and radiotherapy, especially after lumpectomy, and hormonal therapy(tamoxifen, femara).
Systemic therapy consists of chemotherapy, immunotherapy or biological response modifiers or hormone therapy.[6] Oncologists use statistical evidence to assess therisk of disease relapse before deciding on the specific adjuvant therapy.
Since most early-stage endometrial cancer cases are diagnosed early andare typically very curable with surgery, adjuvant therapy is only given after surveillance and histological factors determine that a patient is at high risk for recurrence.
For pre-menopausal females, options to preserve fertility are oftentimes much more complex.[11] For example, breast cancer patients of fertile age oftentimes have to weigh the risks andbenefits associated with starting an adjuvant therapy regimen after primary treatment.
Despite the initial pushback from the breast cancer surgeons who believed that their radical mastectomies were sufficient in removing all traces of cancer,the success of Bonadonna's and Fisher's trials brought adjuvant therapy to the mainstream in oncology.[1] Since then, the field of adjuvant therapy has greatly expanded to include a wide range of adjuvant therapies to include chemotherapy, immunotherapy, hormone therapy, and radiation.
All SCHALI®-MА products demonstrate a strong synergistic effect in therapy of thyroid gland hormone secretion and inhibition of immunosuppression, successfully supplementing anti-fibrotic drugs,and supporting haemostatic effect in adjuvant therapy of haemorrhagic syndrome associated diseases.
In the context of melanoma, certain treatments, such as Ipilimumab, result in high grade adverse events, or immune-related adverse events, in 10-15% of patients that parallel the effects of metastatic melanoma itself.[8][9] Similarly,several common adjuvant therapies are noted for having the potential of causing cardiovascular disease.[10] In such cases, physicians must weigh the cost of future recurrence against more immediate consequences and consider factors, like age and relative cardiovascular health of a patient, before prescribing certain types of adjuvant therapy. .
НМР SCHALI® medical plastershows a strong synergistic effect in complex and adjuvant therapies, resulting in shorter time of treatment.